Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Signal Transfer of Atrial Fibrillation Data to Guide Human Treatment (STARLIGHT)

This study has been completed.
Information provided by (Responsible Party):
Boston Scientific Corporation Identifier:
First received: January 8, 2013
Last updated: March 3, 2014
Last verified: March 2014
The purpose of the study is to gather electrophysiological data using a multi-electrode mapping catheter during a clinically indicated cardiac ablation procedure for the treatment of persistent atrial fibrillation.

Permanent Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Signal Transfer of Atrial Fibrillation Data to Guide Human Treatment

Resource links provided by NLM:

Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Record 20 sets of electrophysiological data with a multi-electrode mapping catheter. [ Time Frame: Acute - time of procedure ]

Enrollment: 25
Study Start Date: April 2013
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Patients undergoing cardiac ablation for permanent AF


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Permanent atrial fibrillation

Inclusion Criteria:

  • Age 18 or above, or above legal age and willing and capable of giving informed consent specific to national law
  • Scheduled for a clinically indicated cardiac ablation for the treatment of persistent atrial fibrillation
  • Able to meet study requirements for follow-up visit

Exclusion Criteria:

  • Permanent leads or presence of prosthetic or severely stenotic tricuspid or mitral valves
  • Active systemic infection or sepsis
  • Echocardiographically confirmed presence of thrombus
  • Atrial thrombus, myxoma, inter-atrial baffle patch or occluder device for those subjects in whom a transseptal approach is required
  • Subjects who cannot be anticoagulated or infused with heparinized saline
  • Heparin induced thrombocytopenia
  • Hemodynamic instability or shock
  • Atrial anatomy contradictory to catheter labeling or size indices
  • EF < 35%
  • Subjects with an active heart failure decompensation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01765075

Czech Republic
Na Homolce
Prague, Czech Republic, 15030
United Kingdom
Guys & St. Thomas' Hospital
London, United Kingdom, SE1 1YR
Sponsors and Collaborators
Boston Scientific Corporation
Principal Investigator: Jas Gill, MA MD FRCP FACC Guys & St. Thomas' Hospital
  More Information

Responsible Party: Boston Scientific Corporation Identifier: NCT01765075     History of Changes
Other Study ID Numbers: STARLIGHT - 1012
Study First Received: January 8, 2013
Last Updated: March 3, 2014

Keywords provided by Boston Scientific Corporation:
Electrophysiological mapping
Multi-electrode catheter

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on May 25, 2017